ClinicalTrials.gg
RecruitingNCT07725562Updated Sep 3, 2026

VG081821AC Tablets for Early to Mid-stage Parkinson's Disease

A Phase 2/3 interventional study of VG081821AC and Placebo in Parkinson Disease (PD), sponsored by Zhejiang Vimgreen Pharmaceuticals, Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Zhejiang Vimgreen Pharmaceuticals, Ltd. · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.

Planned enrollment
37th of 211
152 · median 47
Started
2026
with 40 others
Phase 2/3
5 of 279
1 open now
Primary completion
2027-10
later than 102 of 134 live
Registered
266th of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 37th largest by planned enrollment of the 211 interventional ones that give a count, is one of 41 that started in 2026, is one of 5 in phase 2/3, reaches primary completion later than 102 of the 134 other live ones, and was the 266th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

122 more — sign in →

All 128 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

This study is testing a new oral medication called VG081821AC to see if it can help improve movement symptoms in people with early to mid-stage Parkinson's disease. VG081821AC works by blocking a protein in the brain called the adenosine A2A receptor, which may help improve motor function without using levodopa. The main goal is to measure changes in movement symptoms using a standard rating scale called the MDS-UPDRS Part III (Motor Examination). This scale evaluates how well participants can move, walk, and perform daily activities. The study will compare the scores before and after 12 weeks of treatment to see if VG081821AC improves movement symptoms better than the placebo. Currently, levodopa is the most common treatment for Parkinson's disease, but it can cause side effects over time. If VG081821AC works well, it could offer a new treatment option for people in the early to mid-stages of Parkinson's disease who want to delay or avoid starting levodopa. A total of 152 adults (aged 18-80 years) will be enrolled in this trial in China. Participants will be randomly assigned (like flipping a coin) to one of four groups:

  • VG081821AC 25 mg (taken twice daily)
  • VG081821AC 50 mg (taken twice daily)
  • VG081821AC 75 mg (taken twice daily)
  • Placebo (a pill with no active drug, taken twice daily)

Participants will visit the study center 8 times to have their movement symptoms, safety, and overall health checked.

03

Conditions studied

  • Parkinson Disease (PD)

Browse trials for

Keywords

  • A2A receptor antagonist
  • Adenosine A2A antagonist
  • VG081821AC
  • VG081821
  • KW6002
  • Istradefylline
  • Nourianz
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 ≤ Age ≤ 80 at the time of signing the .
  • Diagnosed with Parkinson's disease per the Chinese Diagnostic Criteria for Parkinson's Disease (2016 Edition), and time from initial diagnosis ≤ 7 years.
  • Modified Hoehn-Yahr scale rated as 1\~3 (inclusive) at screening.
  • MDS-UPDRS Part III score ≥ 22 at screening.
  • Have not taken anti-Parkinson drugs containing levodopa within 4 weeks prior to screening [see main text section 5.7.1] (Note: Patients who have previously taken levodopa-containing anti-Parkinson drugs can participate in this trial after a 4-week ).
  • Patients receiving amantadine and/or anticholinergic drugs prior to screening must have been on a stable treatment regimen for at least 4 weeks prior to screening, and the dose must not change during the study.
  • Women of must have a negative pregnancy test result at screening, and the participant must agree to use approved measures throughout the study period.
  • Must provide written informed consent and be willing and able to comply with the trial protocol (e.g., able to understand and complete questionnaires, follow the visit schedule, and use the medication).

Exclusion criteria

Exclusion Criteria:

  • Presence of any medical condition that may interfere with full participation in the study, including but not limited to the following: current diagnosis of active epilepsy; history of hemolytic anemia, pulmonary embolism, respiratory depression, dementia, active psychiatric disease, severe depression, or malignant tumor.
  • History of congestive heart failure ( functional class 3 or 4) or known \<30%.
  • History of angina pectoris, myocardial infarction, cerebrovascular accident, percutaneous coronary intervention, peripheral arterial bypass surgery, (TIA), or stroke within 3 months prior to screening.
  • History of arrhythmia or presence of uncontrolled arrhythmia, including but not limited to: atrial fibrillation, Wolff-Parkinson-White syndrome, congenital long syndrome, and indicating QTc interval prolongation (defined as male (QTc) > 450 ms, female (QTc) > 470 ms); [Fridericia formula: QTc=QT/(RR\^0.33), where RR represents the standard heart rate value, calculated by dividing 60 by the heart rate].
  • Use of dopamine receptor agonists, monoamine oxidase inhibitors, catechol-O-methyltransferase (COMT) inhibitors, adenosine A2A receptor antagonists, or drugs with dopamine receptor antagonist effects within 4 weeks prior to screening [see main text section 5.7.1]. (Note: For newly diagnosed patients undergoing an acute dopaminergic challenge test-i.e., taking a single dose of levodopa [e.g., Madopar] or dopamine agonist [e.g., Apomorphine]-they can be enrolled after a 3-day ).
  • History of drug or other allergies where the investigator considers participation in this study to be of high risk, or previous allergic reactions to adenosine A2A receptor antagonists, or suspected by the investigator to be allergic to the study drug or any of its components.
  • Plan to take drugs that are inhibitors or inducers of efflux transporters (P-gp, BCRP) during the study period.
  • Suffering from uncontrolled hypertension (treated or untreated) at screening, defined as systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg. (Note: After establishing good blood pressure control within a reasonable timeframe, the investigator may permit re-measuring of blood pressure up to the baseline visit, at their discretion).
  • Presence of hepatic impairment (defined as total and/or direct bilirubin, (ALT) and/or aspartate aminotransferase (AST) above the upper limit of the reference range, and deemed clinically significant by the investigator).
  • Presence of any of the following: positive surface antigen; positive virus antibody; positive Hepatitis E virus antibody; positive (HIV) test; positive Treponema pallidum test.
  • Previous non-response to high-dose levodopa (excluding cases of malabsorption) or previous non-response to adequate dopaminergic therapy.
  • Presence of clinically significant renal impairment ( Ccr \<30mL/min), calculated at screening using the Cockcroft-Gault formula: Ccr (mL/min) = (140 - Age) × Weight (kg) / [72 × Serum Creatinine (SCr) (mg/dL)] (Female × 0.85) or Ccr (mL/min) = (140 - Age) × Weight (kg) / [0.814 × Serum Creatinine (SCr) (μmol/L)] (Female × 0.85).
  • Investigator judges the participant to be at risk for suicide, or if the participant answers "yes" to Question 4 and/or Question 5 of the Suicidal Ideation subscale, or any question on the Suicidal Behavior subscale of the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening.
  • Investigator judges the participant to have severe psychiatric abnormalities (anxiety, depression), with a Hamilton Depression Rating Scale-17 (HAMD-17) score >23, or a Hamilton Anxiety Rating Scale (HAMA) score >21 at screening.
  • Participant has significant cognitive impairment or dementia, including the following scenarios: Illiterate participants (uneducated) with an score ≤19 at screening; Primary school participants (education ≤6 years) with an MMSE score ≤22 at screening; Middle school and above participants (education >6 years) with an MMSE score ≤23 at screening.
  • History of surgical treatment for Parkinson's disease.
  • Use of repetitive transcranial magnetic stimulation, transcranial direct current stimulation, biofeedback therapy, acupuncture, traditional Chinese medicine, and other traditional rehabilitation methods within 4 weeks prior to screening (Note: Patients can participate in this trial after a 4-week washout period).
  • History of heavy alcohol consumption for more than 3 consecutive months within 1 year prior to screening, defined as: female participants drinking an average of >20 g of alcohol daily (calculated as pure alcohol; 20 g is roughly equivalent to two 300 mL glasses of beer, 40 mL of spirits, or 140 mL of wine), and male participants drinking an average of >30 g of alcohol daily (calculated as pure alcohol; 30 g is roughly equivalent to three 300 mL glasses of beer, 60 mL of spirits, or 210 mL of wine), or inability to reliably quantify alcohol consumption according to the investigator's judgment.
  • History of excessive tea and/or coffee consumption within the past 4 weeks, or anticipated excessive consumption during the clinical trial period. (Excessive tea consumption is defined as 4 or more cups a day, 1 cup = 250 mL; second or third steepings without adding new leaves still count as 1 cup total, not two or three. Excessive coffee consumption is defined as 2 or more cups a day, 1 cup = 250 mL; for participants who do not drink coffee every day, 2 cups per day is permissible for one day a week, but no more than 2 cups; and the defined consumption limit must not be exceeded throughout the entire trial).
  • Active substance abuse (including inhaled or injected drugs) within 1 year prior to screening.
  • Participated in another drug clinical trial (meaning received drug treatment) within 3 months prior to randomization.
  • Any other condition where the investigator considers the participant unsuitable for this study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
152 participants (estimated)

Study arms

  • Experimental
    VG081821AC 25 mg BID

    1 active tablet + 2 placebo tablets

    Drug: VG081821AC

  • Experimental
    VG081821AC 50 mg BID

    2 active tablets + 1 placebo tablet

    Drug: VG081821AC

  • Experimental
    VG081821AC 75 mg BID

    3 active tablets

    Drug: VG081821AC

  • Placebo comparator
    Placebo

    3 placebo tablets

    Other: Placebo

Interventions

  • DrugVG081821AC

    VG081821AC Tablets: Oral, small-molecule adenosine A2A receptor antagonist (25 mg/tablet) administered BID within 30 min post-meal for 12 weeks. The study evaluates three active dose levels (25 mg, 50 mg, and 75 mg BID), each administered as a fixed combination of three tablets.

    Also known as: VG081821

  • OtherPlacebo

    An inert placebo tablet identical in appearance, taste, and packaging to the VG081821AC tablet. It contains no active pharmaceutical ingredient and is formulated with the same excipients as VG081821AC. The placebo is administered as a fixed combination of three tablets via the same route and schedule as the active treatment.

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of oral VG081821AC tablets in Chinese patients with early to mid-stage Parkinson's disease

    The endpoint is the change from baseline in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination) score at week 12 for the experimental and placebo groups.

    Time frame: From enrollment to the end of treatment at 12 weeks

Secondary outcomes

  1. To evaluate the types, occurrences, number of cases, and incidence rates of Adverse Events (AEs) and Serious Adverse Events (SAEs) during the study

    Time frame: From enrollment to the end of treatment at 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — IPD Description: De-identified individual participant data (demographics, efficacy, safety), study protocol, statistical analysis plan, informed consent form, and data dictionary will be shared with qualified researchers for non-commercial research. Free-text fields and re-identifiable data excluded. IPD Time Frame: Within 12 months after primary completion date. IPD Access Criteria: Submit research proposal, CV, IRB approval, and signed Data Use Agreement to sponsor. Review by independent committee within 6 weeks. Approved requesters receive secure data transfer. IPD URL: Data sharing requests to welcome@vimgreenpharma.com; portal URL to be established.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Within 12 months after primary completion date.

Access criteria: IPD Access Criteria: Submit research proposal, CV, IRB approval, and signed Data Use Agreement to sponsor. Review by independent committee within 6 weeks. Approved requesters receive secure data transfer.

Data sharing details ↗ · www.vimgreenpharma.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Oct 2027, 14 months after the start.

Of 22 phase 2/3 interventional studies under Parkinson Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 50. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 24, 2026
StartActual
Jul 17, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 31, 2027
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07725562
Lead sponsor
Zhejiang Vimgreen Pharmaceuticals, Ltd.
Responsible party
Sponsor
First posted
Jul 24, 2026
Start date
Jul 17, 2026
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Sep 3, 2026

Study contacts

Yanfen Jin, Ms
Contact
jinyanfen@vimgreenpharma.com
86+57189010903

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion